Larimar Therapeutics, Inc. (NasdaqGM: LRMR)
Health Care · Biotechnology · US
$2.67
-9.80% today · -37.2% 1Y
Larimar Therapeutics, Inc. (NasdaqGM: LRMR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $278.70M and employs 71 people.
Over the last twelve months the share price has lost 37.2%, trading between 2.61 and 6.42.
Tweenvest scores Larimar Therapeutics, Inc. across four factors: quality 37/100, value 45/100. Its strongest factor is value.
LRMR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $278.70M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.93
- Dividend yield
- —
- Beta (5Y)
- 0.69
- 52-week high
- $6.42
- 52-week low
- $2.61
- Avg volume (3M)
- —
- Shares outstanding
- 104.38M
- Employees
- 71
- Next earnings
- —
About Larimar Therapeutics, Inc.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
- ISIN
- US5171251003
- Listed since
- Jun 19, 2014
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Tanvex BioPharma, Inc.TWSE: 6541 | $281.36M | NT$33.95 | +14.70% |
| Rocket Pharmaceuticals, Inc.NasdaqGM: RCKT | $281.02M | $2.56 | 0.00% |
| AIM Vaccine Co., Ltd.SEHK: 6660 | $280.55M | HK$1.80 | +6.85% |
| Clinuvel Pharmaceuticals LimitedASX: CUV | $279.41M | AU$7.94 | +0.13% |
| Vanda Pharmaceuticals Inc.NasdaqGM: VNDA | $276.31M | $4.57 | -1.30% |
| Bicycle Therapeutics plcNasdaqGS: BCYC | $272.27M | $3.89 | +2.10% |
| SAB Biotherapeutics, Inc.NasdaqCM: SABS | $271.14M | $2.98 | 0.00% |
| Palisade Bio, Inc.NasdaqCM: PALI | $268.38M | $1.54 | +6.94% |
Figures last refreshed Oct 11, 2026.